Ernexa Therapeutics Inc. (ERNA) stock
ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
$1.68−0.11 (-6.15%)
Close on Nov 13, 2026Market cap $2.74MP/E –Yield –
Ernexa Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Ernexa Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $582.00K, up 755.9% year over year. For fiscal 2024 it was $582.00K, up 755.9% from the year before. Over ten years it grew -31.0% a year on average. The highest annual figure on record is $26.05M in fiscal 2014.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $582.00K | +755.9% |
| FY2023 | Dec 31, 2023 | $68.00K | – |
| FY2022 | Dec 31, 2022 | $0 | -100.0% |
| FY2020 | Dec 31, 2020 | $5.80M | -70.7% |
| FY2019 | Dec 31, 2019 | $19.81M | -15.1% |
| FY2018 | Dec 31, 2018 | $23.34M | +9.7% |
| FY2017 | Dec 31, 2017 | $21.27M | -4.7% |
| FY2016 | Dec 31, 2016 | $22.31M | -9.0% |
| FY2015 | Dec 31, 2015 | $24.52M | -5.9% |
| FY2014 | Dec 31, 2014 | $26.05M | +9.7% |
| FY2013 | Dec 31, 2013 | $23.75M | -1.3% |
| FY2012 | Dec 31, 2012 | $24.06M | +0.8% |
| FY2011 | Dec 31, 2011 | $23.87M | -5.7% |
| FY2010 | Dec 31, 2010 | $25.31M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $1.00K | -94.1% |
| Q3 FY2024 | Sep 30, 2024 | $487.00K | +854.9% |
| Q2 FY2024 | Jun 30, 2024 | $47.00K | – |
| Q1 FY2024 | Mar 31, 2024 | $47.00K | – |
| Q4 FY2023 | Dec 31, 2023 | $17.00K | – |
| Q3 FY2023 | Sep 30, 2023 | $51.00K | -95.7% |
| Q1 FY2023 | Mar 31, 2023 | $0 | -100.0% |
| Q4 FY2022 | Dec 31, 2022 | $0 | -100.0% |
| Q3 FY2022 | Sep 30, 2022 | $0 | -100.0% |
| Q4 FY2020 | Dec 31, 2020 | $1.18M | -77.3% |
| Q3 FY2020 | Sep 30, 2020 | $1.48M | -67.8% |
| Q2 FY2020 | Jun 30, 2020 | $754.00K | -85.6% |
| Q1 FY2020 | Mar 31, 2020 | $2.39M | -50.5% |
| Q4 FY2019 | Dec 31, 2019 | $5.17M | -12.7% |
| Q3 FY2019 | Sep 30, 2019 | $4.58M | -23.7% |
| Q2 FY2019 | Jun 30, 2019 | $5.23M | -7.5% |
| Q1 FY2019 | Mar 31, 2019 | $4.83M | -16.1% |
| Q4 FY2018 | Dec 31, 2018 | $5.92M | +11.8% |
| Q3 FY2018 | Sep 30, 2018 | $6.00M | +15.5% |
| Q2 FY2018 | Jun 30, 2018 | $5.65M | +1.8% |
| Q1 FY2018 | Mar 31, 2018 | $5.76M | +10.1% |
| Q4 FY2017 | Dec 31, 2017 | $5.30M | -11.4% |
| Q3 FY2017 | Sep 30, 2017 | $5.20M | – |
| Q2 FY2017 | Jun 30, 2017 | $5.55M | – |
| Q1 FY2017 | Mar 31, 2017 | $5.23M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.98M | – |
See a number that looks wrong?